Gsk Plc · LSE:GSK
Gsk — GlaxoSmithKline — FY2006 Earnings Presentation
34 slides from Gsk's earnings presentation, Feb 8, 2007
Slide 1: Full Year Results 2006
Full Year Results 2006 Presentation to Analysts & Investors Full Year 2007 8th February Results 2006 Presentation to the Media 8th February 2007
Slide 2: GSK – the fundamentals
GSK – the fundamentals strong and continued commitment to delivering solid growth broad and dynamic portfolio with significant growth opportunities significant late stage pipeline with strong momentum
Slide 3: 2006 earnings ahead of guidance
2006 earnings ahead of guidance* £ CER Actual Sales 23.2bn 9% 7% Profit Before 7.8bn 19% 16% Tax EPS 95.5p 19% 16% *GSK earnings guidance 8th February 2006: “2006 earnings per share growth expected to be around 10% in CER terms.”
Slide 4: Financial strength
Financial strength Cash generated from operations now exceeds £8bn 9 8.2 8 7 £bn 6 5.4 5 4 3 2000 2006
Slide 5: Financial strength
Financial strength Cash generated from operations Accelerating cash now exceeds £8bn returns to shareholders 9 8.2 Buy-back programme doubled 8 to £6bn over 3 years 7 In 2006, dividend increased £bn 6 5.4 from 44p to 48p 5 4 3 2000 2006
Slide 6: GSK – the fundamentals
GSK – the fundamentals strong and continued commitment to delivering solid growth broad and dynamic portfolio with significant growth opportunities significant late stage pipeline with strong momentum
Slide 7: Strong growth from key Pharma products
Strong growth from key Pharma products +11% +25% CER Growth. Growth shown for Avandia franchise.
Slide 8: Strong growth from key Pharma products
Strong growth from key Pharma products +29% +60% +11% +25% +9% CER Growth. Growth shown for Avandia franchise and hepatitis franchise.
Slide 9: Vaccine sales – doubled this decade
Vaccine sales – doubled this decade – driven by strong growth of new products 2006 vaccine sales £1.7bn +23% MMRV 1800 1600 1400 1200 Sales 1000 800 600 400 2000 2003 2006
Slide 10: Strong growth from key Pharma products
Strong growth from key Pharma products >100% +38% +29% +19% +74% +60% +11% +24% +69% +25% +9% CER Growth. Growth shown for Avandia franchise and hepatitis franchise.
Slide 11: 5 major product launches expected in 2007
5 major product launches expected in 2007
Slide 12: Tykerb – new hope for cancer patients
Tykerb – new hope for cancer patients
Slide 13: Several more sales growth opportunities
Several more sales growth opportunities… H5N1 - - New ACS indication - - pandemic
Slide 14: New Consumer Healthcare growth drivers
New Consumer Healthcare growth drivers… 10 new products in 2007
Slide 15: New Consumer Healthcare growth drivers… alli
New Consumer Healthcare growth drivers… First FDA approved OTC weight-loss medication alli - 50% more weight loss than diet alone
Slide 16: New Consumer Healthcare growth drivers: brand globalisation
New Consumer Healthcare growth drivers… Brand globalisation
Slide 17: GSK – the fundamentals
GSK – the fundamentals strong and continued commitment to delivering solid growth broad and dynamic portfolio with significant growth opportunities significant late stage pipeline with strong momentum
Slide 18: Significant late-stage pipeline progress
Significant late-stage pipeline progress Last 12 months casopitant pazopanib Promacta belimumab HuMax–CD20 gepirone ER Phase III XP13512 Pipeline Meningitis vaccine H5N1 pandemic New generation flu As at 8th Feb 2007
Slide 19: Strong late-stage pipeline
Strong late-stage pipeline 31 major product opportunities in late-stage clinical development: 13 NCEs 6 Vaccines 12 PLEs As at 8th Feb 2007
Slide 20: Pipeline momentum: Reloadability
Pipeline momentum “Reloadability”
Slide 21: Reloadability: Phase II starts
“Reloadabilty” Phase II starts 80 (excluding vaccines & PLEs) 70 60 number of projects 50 40 Industry 30 20 10 0 2001-03 2003-05 Source: CMR (number of development projects starting PII in the year, excluding vaccines and excluding line extensions) Industry = 7 major companies: AZ, JJ, Merck, Novart
Slide 22: Reloadability: Phase II starts
“Reloadabilty” Phase II starts 80 (excluding vaccines & PLEs) 70 60 number of projects 50 40 Industry GSK 30 20 10 0 2001-03 2003-05 Source: CMR (number of development projects starting PII in the year, excluding vaccines and line extensions) Industry = 7 major companies: AZ, JJ, Merck, Novartis, Pf
Slide 23: Reloadability: Phase II starts
“Reloadabilty” Phase II starts 80 (excluding vaccines & PLEs) 70 60 number of projects 50 Industry 40 GSK 30 GSK secondary indications 20 10 0 2001-03 2003-05 Source: CMR (number of development projects starting PII in the year, excluding vaccines and line extensions) Industry = 7 major companies: A
Slide 24: GSK’s unique CEDD structure is evolving
GSK’s unique CEDD structure is evolving oncology respiratory biopharm GSK metabolic Pipeline CV & Urol psychiatry Neuro/GI CEEDD
Slide 25: GSK’s unique CEDD structure is evolving
GSK’s unique CEDD structure is evolving oncology respiratory Infec Dis biopharm GSK metabolic Pipeline CV & Urol psychiatry Neuro/GI CEEDD
Slide 26: GSK’s unique CEDD structure is evolving
GSK’s unique CEDD structure is evolving oncology respiratory Infec Dis biopharm macrolide GSK metabolic Pipeline Inflamm CV & Urol psychiatry Neuro/GI CEEDD
Slide 27: GSK’s unique CEDD structure is evolving
GSK’s unique CEDD structure is evolving oncology respiratory Infec Dis biopharm macrolide GSK metabolic Pipeline Inflamm CV & Urol psychiatry Neuro/GI CEEDD
Slide 28: GSK’s unique CEDD structure is evolving
GSK’s unique CEDD structure is evolving oncology respiratory Infec Dis biopharm macrolide GSK metabolic Pipeline Inflamm CV & Urol psychiatry Neuro/GI CEEDD
Slide 29: CEEDD captures access to new pipelines
CEEDD captures access to 15 new pipelines CV & Urol hiatry Neuro/GI CEEDD
Slide 30: Globalisation of R&D
Globalisation of R&D
Slide 31: Globalisation of R&D
Globalisation of R&D Croatia 2006 China 2007
Slide 32: Breaking down the barriers to healthcare
Breaking down the barriers to healthcare
Slide 33: GSK – well positioned…
GSK – well positioned… …Strong and continued commitment to delivering solid financial growth 3 …Broad and dynamic portfolio with significant growth opportunities 3 …Strength and depth across the pipeline 3 ...Fast “reloadability” 3
Slide 34: GlaxoSmithKline
GlaxoSmithKline